US Bancorp
EPZM

US Bancorp’s Epizyme, Inc EPZM Stock Holding History

US Bancorp’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,547
Closed -$2K – 4317
2022
Q1 		$2K Sell
1,547
-1,925
-55% -$3.14K ﹤0.01% 3895
2021
Q4 		$8K Buy
3,472
+355
+11% +$1.4K ﹤0.01% 3526
2021
Q3 		$16K Buy
3,117
+830
+36% +$5.04K ﹤0.01% 3256
2021
Q2 		$19K Buy
2,287
+671
+42% +$5.66K ﹤0.01% 3175
2021
Q1 		$14K Buy
1,616
+491
+44% +$5.08K ﹤0.01% 3181
2020
Q4 		$13K Hold
1,125
– – ﹤0.01% 3100
2020
Q3 		$14K Buy
+1,125
New +$15.1K ﹤0.01% 2967
2017
Q1 		– Sell
-2,000
Closed -$24K – 3669
2016
Q4 		$24K Hold
2,000
– – ﹤0.01% 2767
2016
Q3 		$20K Hold
2,000
– – ﹤0.01% 2815
2016
Q2 		$20K Hold
2,000
– – ﹤0.01% 2807
2016
Q1 		$24K Hold
2,000
– – ﹤0.01% 2704
2015
Q4 		$32K Hold
2,000
– – ﹤0.01% 2643
2015
Q3 		$26K Buy
+2,000
New +$40.4K ﹤0.01% 2763

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

US Bancorp's EPZM Position: Q2 2022 in Review

US Bancorp sold out of Epizyme, Inc (EPZM) in Q2 2022, closing a stake of 1,547 shares — an estimated $2K sold.

US Bancorp first reported a position in EPZM in Q3 2015 and held it in 13 quarters. The position peaked at $32K in Q4 2015. 93 funds tracked by Wall St. Rank hold EPZM as of Q2 2022.

  • US Bancorp reported no remaining Epizyme, Inc position as of Q2 2022 after selling out during the quarter.
  • US Bancorp sold 1,547 Epizyme, Inc shares in Q2 2022, an estimated $2K.
  • US Bancorp first reported a position in Epizyme, Inc in Q3 2015 and held it in 13 quarters.
  • US Bancorp's Epizyme, Inc position peaked at $32K in Q4 2015.
  • 93 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2022.

Based on US Bancorp's 13F filing for Q2 2022, filed 1 Aug 2022.